In September 2000, Dr. Shrotriya joined the Company as President and Chief Operating Officer and in August 2002, he was appointed Chief Executive Officer. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.
Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.
Dr. Arora, 69, was nominated for election by the board of directors upon the recommendation of the Nominating and Corporate Governance Committee, which was acting upon the recommendation of
Dr. Stuart M. Krassner. Dr. Arora has been providing consulting services to Spectrum since February 2010.
Dr. Arora is a business executive with global experience in driving strategic thinking, management and implementation of operations for drug development
worldwide. Dr. Arora has provided consulting services to senior management at several pharmaceutical companies, including Astellas Pharma Global Development, Inc., for global drug development, from
May 2008 to June 2009, and UCB, Inc., for applications in global regulatory affairs, electronic document management, pharmacovigilance and worldwide quality assurance and compliance, from November 2003 to February 2006. Prior to that, Dr. Arora held senior management positions with several pharmaceutical companies, including Vice President of R&D Global Regulatory Affairs for Management Information at Pfizer Inc. from 1998 to 2003, Senior Director of Regulatory Affairs at Novartis AG from 1993 to 1998 and
Group Director of Biometrics Operations at Sanofi-Aventis. In addition, from 1994 to 2003, Dr. Arora served as Chairman of the Electronic Regulatory Submissions Working Group at PhRMA, which consisted of business and information technology experts from the FDA and 20 biopharmaceutical companies and was the PhRMA lead at ICH on establishing electronic standards for submission of marketing applications to regulatory authorities.
Dr. Arora received a B.Sc. in
Mathematics, Physics and Chemistry from Lucknow University in India, a B.Sc. (Honors) in Agriculture and a M.Sc. in Animal Genetics from G. B. Pant University of Agriculture & Technology in India and a Ph.D. in Population Genetics from Iowa State University.
Dr. Arora has significant experience in the pharmaceutical industry, which includes 11 years' experience in global regulatory affairs and 18 years' experience in biometrics operations, including statistics, clinical data systems, clinical data management and medical writing. Furthermore, Dr. Arora has operational management experience, a keen understanding of the regulatory environment in which pharmaceutical companies operate and extensive knowledge in drug development
operations and regulatory submissions and approvals. As a result, Dr. Arora is well qualified to serve on our board of directors.
Dr. Krassner's career spans nearly four decades of experience in positions of increasing responsibility at the University of California at Irvine, most recently as Professor of Developmental and Cell Biology at the School of Biological Sciences. While at University of California, Irvine (UCI), he developed and reinforced FDA and NIH compliance procedures for UCI-sponsored human clinical trials, established UCI's first Institutional Review Board, and at one time headed all contract and grant activities. Dr. Krassner has also been retained by pharmaceutical, medical device and other companies, including Allergan Pharmaceuticals, Lasermed Corporation, Automated Microbiology Systems, and In Vitro International, among others, to provide scientific and regulatory advisory services, including FDA compliance.
Dr. Krassner's work has been published in numerous peer-reviewed U.S. journals. He is Professor Emeritus, University of California, Irvine, and has lectured at both U.S. and international academic institutions, including Harvard Medical School, Rockefeller University, Johns Hopkins University, St. Petersburg University and University of Edinburgh, among others.
Dr. Krassner is a member of the American Academy for the Advancement of Sciences, and the American Society of Tropical Medicine and Hygiene, among others. Dr. Krassner received his Sc.D. from the Bloomberg School of Public Health at Johns Hopkins University. He holds a B.S. in Biology from Brooklyn College.
Dr. Lenaz, 69, served as Spectrum's Chief Scientific Officer from February 2005 to June 2008 and as President of Spectrum's Oncology Division from 2000 to 2005. Since retiring as Spectrum's Chief Scientific Officer in June 2008, Dr. Lenaz has provided consulting services to Spectrum.
From 1997 to 2000, Dr. Lenaz served as Senior Vice President of Clinical Research, Medical Affairs at Supergen, Inc., a NASDAQ listed pharmaceutical company dedicated to cancer drug development. Dr. Lenaz held several senior management positions with Bristol-Myers Squibb, a NYSE-listed company, including Senior Vice-President of Oncology Franchise Management from 1990 to 1997, and Director of Scientific Affairs, Anti-Cancer from 1985 to 1990. Dr. Lenaz is also a prominent researcher, having conducted research in the areas of pharmacology, experimental chemotherapy, histology, general physiology, and experimental therapeutics at various institutions for cancer research, including Roswell Park Memorial Institute, Memorial Sloan-Kettering Cancer Center and the National Cancer Institute in Milan. He is a member of several scientific societies, including the American Association for Cancer Research, American Association for Clinical Oncology, European Society for Medical Oncology, and International Association for the Study of Lung Cancer.
Dr. Lenaz has served as a director of Pharmaco-Kinesis Corporation, a privately held medical device company since January 2009.
Dr. Lenaz is a graduate of Liceo Scientifico A. Righi in Bologna, Italy and he recieved his medical degree from the University of Bologna Medical School in 1966.
Dr. Lenaz is a renowned and accomplished oncologist who will bring to the Board of Directors over 35 years experience in the pharmaceutical industry and a wealth of knowledge in the field of cancer drug development.
Dr. Lenaz's qualifications to serve on the Board of Directors include his expertice in the development of cancer drugs, his tenure as our Chief Scientific Officer, as well as his subsequent consulting services for our Company, his managmenet experience with Bristol-Myers Squibb, and his prominent research in the field of oncology.
Mr. Maida's career spans nearly 27 years, of which 15 were spent as CEO of emerging biotechnology companies, most with an oncology focus. In addition, Mr. Maida has nearly a decade of financial experience, ending as a Senior Financial Controller of a $1.7 billion division of Lockheed Missiles and Space Company, and VP, CFO of Dataplant Inc., a wholly owned subsidiary of Lockheed.
Mr. Maida is a founder and currently serves as Chairman of BioConsul Drug Development Corporation and DendriTherapeutics, Inc., and has also been retained by pharmaceutical companies, and New York investment and venture capital firms, including North Sound Capital, to provide technical and corporate advisory services. Mr. Maida serves on the Advisory Board of Innovera Life Sciences Fund and Novel Bioventures LLC , and the Scientific Advisory Board of EndPoint Ventures.
Mr. Maida received his Master's Degree in Toxicology from San Jose State University, and received an MBA from University of Santa Clara. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and the American Association of Immunologists, among others.
Dr. Mehta, 77, was nominated for election by the board of directors upon the recommendation of the Nominating and Corporate Governance Committee, which was acting upon the recommendation of Dr. Stuart M. Krassner. Dr. Mehta served on Spectrum's board of directors from June 2003.
br>Dr. Mehta has been selfemployed
as a pharmaceutical consultant since 1998 and has provided consulting services to Spectrum since July 2007. Dr. Mehta is a venture partner at Radius Ventures, LLC in New York. From 1982 until his retirement in 1997, Dr. Mehta held several senior management positions with Pfizer Inc., including Senior Vice President, U.S. Clinical Research, with responsibility for clinical research (Phases 1, 2 and 3) including data processing and statistical analysis for Pfizer's drugs in the U.S., as well as supervised submissions of new drug applications for Cardura, Norvasc, Zoloft, Zithromax, Diflucan, Unasyn, Trovan, Viagra, Geodon, and a number of other drugs/supplements.
Dr. Mehta served as Chairman of the board of directors of Quintiles Spectral (India) Limited (Ahmedabad, India) from 1998 to 2001 and as a member of the board of directors of Bharat Serums & Vaccines Limited (Mumbai, India) from 2006 to 2008 and Targanta Therapeutics Corporation, a NASDAQ-listed biopharmaceutical company acquired by The Medicines Company in February 2009, from 2005 to 2009. From 1993 to 1997, Dr. Mehta served as Chair, Efficacy Section for the Pharmaceutical Research and Manufacturers of America, or PhRMA, in the International Conference on Harmonization and was a PhRMA topic leader for one of the Expert Working Group in Efficacy. From 1966 to 1982, Dr. Mehta held the position of Group Director, Clinical Research in the U.S. for Hoechst AG with supervision of Internal Medicine, Metabolic and Infectious Diseases and Cardiovascular groups.
Dr. Mehta received an M.D., an M.B.B.S. (Bachelor of Medicine and Bachelor of Surgery—equivalent to an M.D.
degree in the U.S.) and a Ph.D. from the University of Bombay. Dr. Mehta was a Research Fellow in Clinical Pharmacology at Cornell University Medical College.
Dr. Mehta brings to the board of directors over 28 years' experience in the pharmaceutical industry and a wealth of knowledge in the field of clinical research and drug development. Dr. Mehta's qualifications to serve on the board of directors include his expertise in clinical research, drug development and FDA matters, his prior service on Spectrum's board of directors, as well as his service on the boards of directors of other publicly traded and privately held biopharmaceutical companies and his significant management experience with Pfizer. As a result, Dr. Mehta is well qualified to serve on our board of directors.
Stock transaction information provided by EDGAR Online. Spectrum Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
Stock Information
NASDAQ:SPPI
$3.86+ 0.08
Sep 2, 2010
4:00 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
= Chair
= Member
Chairman, Chief Executive Officer and President
